Is Freenome, Inc. Common stock (FRNM) a Buy, Sell, or Hold?
NASDAQ : FRNM
Freenome, Inc. Common stock — News
$11.15 USD
$0.24 (2.2%)
- Volume
- 548.63K
- Average Volume
- 242.62K
- Market Capitalization
- $90.95M
- P/E Ratio
- Dividend Yield
- %
- Price Target
- Year High
- $14.47
- Year Low
- $9.95
- Day High
- —
- Day Low
- —
- Payout Ratio
- Current Ratio
| Source | Headline |
|---|---|
|
FDA approves Freenome's blood test for colorectal cancer screening
The U.S. FDA has approved Freenome's blood-based colorectal cancer screening test for older adults, paving the way for partner Abbott to launch it in the U.S. this fall, the companies said on Monday. reuters.com - 2026-07-27 09:15:01 |
|
FDA Approves Freenome's SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
– Approval expands colorectal cancer screening options for the up to 60 million Americans who are overdue for screening – – Medicare coverage and American Cancer Society guidance support broader access to blood-based colorectal cancer screening – BRISBANE, Calif. and ABBOTT PARK, Ill. globenewswire.com - 2026-07-27 08:00:00 |
|
Freenome Debuts as a Publicly Traded Company Focused on Blood-Based Early Cancer Detection
– Freenome common stock expected to begin trading on the Nasdaq Capital Market under the ticker symbol "FRNM" on July 21, 2026 – – Gross proceeds to Freenome totaled more than $300 million through a PIPE, led by Perceptive Advisors and RA Capital, and funds held by Perceptive Capital Solutions Corp's trust account – – Capital will support Freenome's cancer screening portfolio, AI/ML-enabled multiomics platform and commercial infrastructure - BRISBANE, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Freenome Holdings, Inc. ("Freenome") (Nasdaq: FRNM), an early cancer detection company developing blood-based screening tests, today announced the closing of its previously announced business combination with Perceptive Capital Solutions Corp. (formerly Nasdaq: PCSC) ("PCSC"). globenewswire.com - 2026-07-20 16:01:00 |
